FDA advisors recommend Eli Lilly Alzheimer’s drug that slows disease

FDA advisors recommend Eli Lilly Alzheimer’s drug that slows disease


A highly anticipated Alzheimer’s medication from Eli Lilly gained the support of a federal advisory panel Monday, paving the way for it to become the second drug of its kind authorized in the United States.

An 11-member advisory committee for the Food and Drug Administration voted unanimously Monday afternoon that the drug’s ability to slow disease progression outweighs the drug’s potentially severe side effects, including brain swelling and bleeding.

If the entire FDA were to approve the new medication, donanemab, it would make it the second Alzheimer’s drug the agency approved for use in the U.S., following Leqembi’s approval last year.

Trending: Beach Disaster: Quicksand Swallows Woman as She Screams for Husband to Rescue Her – ‘I Can’t Get Out!’

The clinical trials for donanemab conducted by Eli Lilly grouped patients based on their levels of tau, a brain protein whose presence predicts the

Continue reading


 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!